Landmark Research Studies

The objective of the HOPE-3 study was to evaluate whether a cholesterol-lowering drug (rosuvastatin) and a combination blood pressure-lowering pill (candesartan/hydrochlorothiazide) used alone or together can reduce the risk of heart attack, stroke and their sequelae in people without known heart disease at average risk.

HOPE-3 was the largest ongoing trial evaluating the polypill concept in primary prevention, which had a significant impact on primary prevention strategies globally.

Co-Primary endpoints:

  • The composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
  • The composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure and arterial revascularizations.

Secondary endpoints:

  • Total mortality and the components of the co-primary endpoints.
  • Additional endpoints include progression of renal disease, new diagnosis of diabetes, cognitive function and erectile dysfunction in men.

All primary and secondary endpoints were adjudicated.

HOPE-3 Results 2016 - Download PDF
Study Type

Interventional - Drug

Study Design

Randomized, double-blind, placebo control, factorial assignment

NO. of Countries


NO. of Sites


NO. of Participants


Study Period




VIDEO: Eva Lonn, Jackie Bosch and Salim Yusuf present on HOPE-3 at ACC 2016


Back To Top